Monoclonal antibodies and oral antiviral drugs are in use for the home management of patients with mild to moderate Covid-19. Clinical trials that support their use have provided scientifical evidence about their safety and effectiveness, and the aim of this thesis is to evaluate them in the real clinical practice. Purpose of this pharmacoepidemiological analysis is to select a cohort of patients who had a confirmed SARS-CoV-2 infection and were treated with monoclonal antibodies (bamlanivimab, bamlanivimab+etesevimab, sotrovimab, casirivimab+imdevimab) or oral antivirals (Paxlovid, Lagevrio). Then, the data obtained will be used to characterize the subjects who had access to these treatments, and to test their effectiveness, even considering the evolution of the epidemiological situation due to the spread of viral variants.
Farmaci antivirali orali (Paxlovid, Lagevrio) e anticorpi monoclonali (bamlanivimab, bamlanivimab+etesevimab, sotrovimab, casirivimab+imdevimab) sono in uso per il trattamento di pazienti non ospedalizzati con forme di Covid-19 da lieve a moderato e i trial clinici che ne supportano l’utilizzo hanno fornito evidenze scientifiche in merito alla loro efficacia sui soggetti su cui sono stati testati, prevalentemente privi di copertura vaccinale. Lo scopo di questa tesi è di descrivere in un contesto di real clinical practice la modalità di utilizzo e gli esiti osservati, anche in relazione all’evoluzione della situazione epidemiologica dovuta alla diffusione delle varianti virali.
Analisi dell'impiego di farmaci antivirali orali e anticorpi monoclonali per il trattamento del Covid-19 di grado lieve-moderato a rischio di progressione verso forme severe: l'esperienza del Distretto n.2 Azienda ULSS 3 Serenissima
FANTELLI, MARTINA
2021/2022
Abstract
Monoclonal antibodies and oral antiviral drugs are in use for the home management of patients with mild to moderate Covid-19. Clinical trials that support their use have provided scientifical evidence about their safety and effectiveness, and the aim of this thesis is to evaluate them in the real clinical practice. Purpose of this pharmacoepidemiological analysis is to select a cohort of patients who had a confirmed SARS-CoV-2 infection and were treated with monoclonal antibodies (bamlanivimab, bamlanivimab+etesevimab, sotrovimab, casirivimab+imdevimab) or oral antivirals (Paxlovid, Lagevrio). Then, the data obtained will be used to characterize the subjects who had access to these treatments, and to test their effectiveness, even considering the evolution of the epidemiological situation due to the spread of viral variants.File | Dimensione | Formato | |
---|---|---|---|
Fantelli_Martina.pdf
accesso riservato
Dimensione
2.53 MB
Formato
Adobe PDF
|
2.53 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/35715